Compositions and methods for surface abrasion with frozen particles

• US 20100114267A1
• Filed: 10/31/2008
• Published: 05/06/2010
• Est. Priority Date: 10/31/2008
• Status: Active Grant

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Myhrvold, Nathan P., Boyden, Edward S., Wood, Lowell L. JR., Hyde, Roderick A., Sweeney, Elizabeth A., Leuthardt, Eric C., Cook, Daniel B.
• Granted Patent: US 8,762,067 B2
• Time in Patent Office: Days
• US Class Current: 607/96
• CPC Class Codes: A61B 17/3203 Fluid jet cutting instruments
• CPC Class Codes: A61B 18/02 by cooling, e.g. cryogenic techniques devices for cooling specific reflex points of the body within cell-life limits A61H39/06
• CPC Class Codes: A61B 2017/00022 Sensing or detecting at the treatment site
• CPC Class Codes: A61B 2017/00128 related to intensity or progress of surgical action
• CPC Class Codes: A61B 2034/101 Computer-aided simulation of surgical operations
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/574 for cancer
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.

Claims

1. A method, comprising:

comparing information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one subject, and information regarding at least one clinical outcome following receipt by the at least one subject of at least one frozen particle composition; and

providing output information.

2. The method of claim 1, further comprising determining at least one statistical correlation.

3. The method of claim 1, further comprising counting the occurrence of at least one clinical outcome.

4. The method of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding quantity of cells or tissue removed or destroyed.

5. The method of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one dimension of cellular, tissue, or other material removal or destruction.

6. The method of claim 5, wherein information regarding the at least one dimension of cellular, tissue, or other material removal or destruction includes information regarding at least one of depth, width, or breadth of cellular, tissue, or other material removal or destruction.

7. The method of claim 1, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding two or more subjects with one or more common attributes.

8. The method of claim 7, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes.

9. The method of claim 8, wherein the one or more common attributes include genotype attributes or phenotype attributes.

10. The method of claim 9, wherein the one or more common attributes include at least one of height;

weight;

medical diagnosis;

familial background;

results on one or more medical tests;

ethnic background;

body mass index;

age;

presence or absence of at least one disease or condition;

species;

ethnicity;

race;

allergies;

gender;

thickness of epidermis;

thickness of dermis;

thickness of stratum corneum;

keratin deposition;

collagen deposition;

blood vessel condition;

skin condition;

hair or fur condition;

muscle condition;

tissue condition;

organ condition;

nerve condition;

brain condition;

presence or absence of at least one biological, chemical, or therapeutic agent in the subject;

pregnancy status;

lactation status;

genetic profile;

proteomic profile;

partial or whole genetic sequence;

partial or whole proteomic sequence;

medical history;

lymph condition, or blood condition.

11. The method of claim 1, wherein the output information includes at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination administered;

a code indicative of at least one therapeutic agent administered;

a code indicative of at least one diagnostic agent administered;

a code indicative of at least one interaction of an administered agent and at least one biological or chemical agent in the subject;

a code indicative of at least one dispersion or location of at least one administered agent;

a code indicative of at least one detection material administered;

a code indicative of the depth of penetration of a administered agent;

or a code indicative of the condition of at least one location of an administered frozen particle composition.

12. The method of claim 1, wherein the at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one cellular or tissue source.

13. The method of claim 12, wherein the information regarding at least one tissue source includes information regarding at least one abnormal cellular or tissue source.

14. The method of claim 12, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue.

15. The method of claim 1, wherein the at least one frozen particle composition includes at least one of polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer'"'"'s solution, lactated Ringer'"'"'s solution, Hartmann'"'"'s solution, acetated Ringer'"'"'s solution, phosphate buffered solution, TRIS-buffered saline solution, Hank'"'"'s balanced salt solution, Earle'"'"'s balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, diethyl ether, nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, chlorine, bromine, oxygen, air or argon.

16. The method of claim 1, wherein the at least one frozen particle composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween.

17. The method of claim 1, wherein the at least one frozen particle composition includes one or more reinforcement agents.

18. The method of claim 1, wherein the at least one frozen particle composition includes one or more explosive materials.

19. The method of claim 1, wherein the receipt by the at least one subject of at least one frozen particle composition is pursuant to at least one clinical trial.

20. The method of claim 1, further comprising determining at least one correlation before the administration of the at least one frozen particle composition to at least one subject.

21. The method of claim 20, further comprising creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one frozen particle composition.

22. The method of claim 1, wherein comparing the information further comprises suggesting the inclusion of one or more of the at least one subject in at least one clinical trial.

23. The method of claim 1, wherein comparing the information further comprises suggesting the exclusion of one or more of the at least one subject in at least one clinical trial.

24. The method of claim 1, further comprising using one or more of the at least one correlation to predict at least one clinical outcome regarding at least one second subject.

25. The method of claim 24, wherein the at least one second subject has not received the at least one frozen particle composition.

26. The method of claim 24, wherein the at least one second subject is a plurality of people;

and further comprising segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome.

27. The method of claim 24, wherein the at least one second subject is a plurality of people;

and further comprising determining the eligibility of the at least one second subject for the at least one clinical trial.

28. A method of predicting a clinical outcome of at least one frozen particle composition treatment for at least one first subject, comprising:

determining a similarity or a dissimilarity in information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one first subject to information regarding at least one aspect of cellular or tissue abrasion or ablation of at least one biological tissue of at least one second subject, wherein the at least one second subject attained a clinical outcome following receipt of the at least one frozen particle composition; and

providing output information.

29. The method of claim 28, wherein the output information is based on the determination.

30. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding quantity of cells or tissue removed or destroyed.

31. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one dimension of cellular, tissue, or other material removal or destruction.

32. The method of claim 31, wherein the at least one dimension of cellular, tissue, or other material removal or destruction includes information regarding at least one depth, width, or breadth of cellular, tissue, or other material removal or destruction.

33. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding two or more subjects with one or more common attributes.

34. The method of claim 33, wherein the one or more common attributes include genetic attributes, mental attributes, or psychological attributes.

35. The method of claim 33, wherein the one or more common attributes include genotype attributes or phenotype attributes.

36. The method of claim 33, wherein the one or more common attributes include at least one of height;

weight;

medical diagnosis;

familial background;

results on one or more medical tests;

ethnic background;

body mass index;

age;

presence or absence of at least one disease or condition;

species;

ethnicity;

race;

allergies;

gender;

thickness of epidermis;

thickness of dermis;

thickness of stratum comeum;

keratin deposition;

collagen deposition;

blood vessel condition;

skin condition;

hair or fur condition;

muscle condition;

tissue condition;

organ condition;

nerve condition;

brain condition;

presence or absence of at least one biological, chemical, or therapeutic agent in the subject;

pregnancy status;

lactation status;

genetic profile;

proteomic profile;

partial or whole genetic sequence;

partial or whole proteomic sequence;

medical history;

lymph condition, or blood condition.

37. The method of claim 28, wherein the output information includes at least one of a response signal, a comparison code, a comparison plot, a diagnostic code, a treatment code, a test code, a code indicative of at least one treatment received, a code indicative of at least one prescribed treatment step, a code indicative of at least one vaccination administered;

a code indicative of at least one therapeutic agent administered;

a code indicative of at least one diagnostic agent administered;

a code indicative of at least one interaction of an administered agent and at least one biological or chemical agent in the subject;

a code indicative of at least one dispersion or location of at least one administered agent;

a code indicative of at least one detection material administered;

a code indicative of the depth of penetration of a administered agent;

or a code indicative of the condition of at least one location of a administered frozen particle composition.

38. The method of claim 28, wherein the information regarding at least one aspect of cellular or tissue abrasion or ablation includes information regarding at least one cellular or tissue source.

39. The method of claim 38, wherein the information regarding at least one tissue source includes information regarding at least one abnormal cellular or tissue source.

40. The method of claim 38, wherein the information regarding at least one cellular or tissue source includes information regarding at least one type of cell or tissue.

41. The method of claim 28, wherein the at least one frozen particle composition includes at least one of polyethylene glycol, acetone, ethyl acetate, dimethyl sulfoxide, dimethyl formamide, dioxane, hexamethylphosphorotriamide, perfluorohydrocarbon, methanol, ethanol, tert-butyl alcohol, formic acid, hydrogen fluoride, ammonia, acetic acid, benzene, carbon tetrachloride, acetonitrile, hexane, methylene chloride, carboxylic acid, saline, Ringer'"'"'s solution, lactated Ringer'"'"'s solution, Hartmann'"'"'s solution, acetated Ringer'"'"'s solution, phosphate buffered solution, TRIS-buffered saline solution, Hank'"'"'s balanced salt solution, Earle'"'"'s balanced salt solution, standard saline citrate, HEPES-buffered saline, dextrose, glucose, diethyl ether, nitrogen, carbon dioxide, hydrogen oxide, helium, neon, xenon, krypton, chlorine, bromine, oxygen, air or argon.

42. The method of claim 28, wherein the at least one frozen particle composition includes at least one major dimension of approximately one centimeter or less, approximately one millimeter or less, approximately one micrometer or less, approximately one nanometer or less, or any value therebetween.

43. The method of claim 28, wherein the at least one frozen particle composition includes one or more reinforcement agents.

44. The method of claim 28, wherein the at least one frozen particle composition includes one or more explosive materials.

45. The method of claim 28, wherein the receipt by the at least one subject of at least one frozen particle composition is pursuant to at least one clinical trial.

46. The method of claim 28, further comprising creating at least one inclusion criterion and at least one exclusion criterion for a clinical trial involving the at least one frozen particle composition.

47. The method of claim 28, further comprising suggesting the inclusion of one or more of the at least one subject in at least one clinical trial.

48. The method of claim 28, further comprising suggesting the exclusion of one or more of the at least one subject in at least one clinical trial.

49. The method of claim 28, further comprising determining at least one correlation before the administration of the at least one frozen particle composition to at least one subject.

50. The method of claim 49, further comprising using at least one correlation to predict at least one clinical outcome regarding at least one other subject.

51. The method of claim 49, wherein the at least one other subject has not received the at least one frozen particle composition.

52. The method of claim 49, wherein the at least one other subject is a plurality of people;

and further comprising segregating subject identifiers associated with the plurality of people in reference to the predicted at least one clinical outcome.

53. The method of claim 49, further comprising determining the eligibility of the at least one other subject for the at least one clinical trial.